BRPI0417549A - miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal - Google Patents

miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal

Info

Publication number
BRPI0417549A
BRPI0417549A BRPI0417549-2A BRPI0417549A BRPI0417549A BR PI0417549 A BRPI0417549 A BR PI0417549A BR PI0417549 A BRPI0417549 A BR PI0417549A BR PI0417549 A BRPI0417549 A BR PI0417549A
Authority
BR
Brazil
Prior art keywords
optic
treatment
superoxide dismutase
nerve injury
retinal nerve
Prior art date
Application number
BRPI0417549-2A
Other languages
English (en)
Inventor
Peter G Klimko
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BRPI0417549A publication Critical patent/BRPI0417549A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MIMéTICOS DE SUPERóXIDO DISMUTASE PARA O TRATAMENTO DE LESãO DE NERVO óPTICO E RETINAL". A presente invenção refere-se a métodos para prevenir e tratar lesão ao nervo óptico e/ou à retina pelo uso de miméticos de SOD, particularmente miméticos de SOD de complexo de penta-azaciclo Mn¬ (II)¬.
BRPI0417549-2A 2003-12-11 2004-11-30 miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal BRPI0417549A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52883003P 2003-12-11 2003-12-11
PCT/US2004/039830 WO2005060974A1 (en) 2003-12-11 2004-11-30 Superoxide dismutase mimics for the treatment of optic nerve and retinal damage

Publications (1)

Publication Number Publication Date
BRPI0417549A true BRPI0417549A (pt) 2007-03-27

Family

ID=34710102

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417549-2A BRPI0417549A (pt) 2003-12-11 2004-11-30 miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal

Country Status (12)

Country Link
US (3) US20050130951A1 (pt)
EP (1) EP1691815A4 (pt)
JP (1) JP2007513948A (pt)
KR (1) KR20060101501A (pt)
CN (1) CN1889961A (pt)
AU (1) AU2004305531B2 (pt)
BR (1) BRPI0417549A (pt)
CA (1) CA2545762A1 (pt)
MX (1) MXPA06006187A (pt)
RU (1) RU2006124746A (pt)
WO (1) WO2005060974A1 (pt)
ZA (1) ZA200603347B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US20190388548A1 (en) * 2018-06-26 2019-12-26 Tzu Chi University Method for providing ocular neuroprotection or for preventing, treating or alleviating the effects of, an ocular disease associated with retinal ganglion cell death

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
ATE68346T1 (de) 1987-07-22 1991-11-15 Farvalsa Ag Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung.
US6127356A (en) * 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5994339A (en) * 1993-10-15 1999-11-30 University Of Alabama At Birmingham Research Foundation Oxidant scavengers
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
AU5251999A (en) 1998-08-04 2000-02-28 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
WO2000023568A2 (en) 1998-10-06 2000-04-27 Albert Einstein College Of Medicine Of Yeshiva University Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
US7445641B1 (en) 1999-05-27 2008-11-04 Pharmacia Corporation Biomaterials modified with superoxide dismutase mimics
CN1620325A (zh) * 2001-12-14 2005-05-25 艾尔科公司 治疗眼睛障碍和疾病的超氧化物歧化酶模拟物
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage

Also Published As

Publication number Publication date
AU2004305531A1 (en) 2005-07-07
EP1691815A1 (en) 2006-08-23
US20110105453A1 (en) 2011-05-05
RU2006124746A (ru) 2008-01-20
KR20060101501A (ko) 2006-09-25
AU2004305531B2 (en) 2009-11-26
CA2545762A1 (en) 2005-07-07
US20050130951A1 (en) 2005-06-16
WO2005060974A1 (en) 2005-07-07
JP2007513948A (ja) 2007-05-31
EP1691815A4 (en) 2010-03-31
CN1889961A (zh) 2007-01-03
ZA200603347B (en) 2009-02-25
MXPA06006187A (es) 2006-08-25
US20070060557A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
BR0210241A (pt) Piranoindazóis e seu uso no tratamento de glaucoma
BR0213975A (pt) Métodos para tratar doenças neovasculares oculares
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
PL396553A1 (pl) Zastosowanie czynnika do wytwarzania leku do leczenia jaskry
WO2002051433A3 (en) Use of artemin, a member of the gdnf ligand family for preparing a neuroprotective medicament
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
CY1108983T1 (el) Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
WO2004052227A3 (en) Superoxide dismutase mimics for the treatment of ocular disorders and diseases
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
EA200300560A1 (ru) Улучшенный способ лечения
WO2002067971A3 (en) Use of endostatin in the treatment of ocular neovascularization
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
BRPI0408889A (pt) uso de clusterina para o tratamento e/ou prevenção de doenças neurológicas periféricas
BR9907715A (pt) Composição oftálmica/método para tratamento de lesão córnea e/ou de estesia córnea deteriordada, sìndrome de olho seco, hipolarcrimação e uso de um inibidor de redutase de aldose
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
WO2004091436A3 (en) Methods and compositions for treating ocular disease
BRPI0612005A2 (pt) agente profilático ou terapêutico, composição oftalmológica, uso de selenoproteína p, e, método de prevenção/tratamento de uma doença corneal/conjuntival
BR0201889A (pt) Vacinas de ige não-anafilactogênicas
BR0017168A (pt) Piranoindóis para tratamento de glaucoma
BR0317021A (pt) Imitadores da superóxido dismutase para o tratamento de distúrbios e de doenças oculares
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 8A E 9A ANUIDADES.

B08I Application fees: publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A, 9A, 10A, 11A, 12A, 13A, 14A E 15A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.